WuXi ATU - Janssen ink licensing agreement for TESSA technology

By Pranali Mehta  | Date: 2022-08-13

WuXi ATU - Janssen ink licensing agreement for TESSA technology

WuXi AppTec’s wholly owned subsidiary, WuXi Advanced Therapies and Janssen Biotech, Inc. have reportedly signed a licensing agreement. Under the terms of the deal, WuXi ATU will license its high-performance TESSA technology, which can produce 10 times more AAV (adeno-associated viral) vectors than conventional AAV production systems, to Janssen.

In addition, Janssen would also gain access to the company’s proprietary clonal suspension HEK293 cell line as part of the agreement, which was facilitated by Johnson & Johnson Innovation.

For the record, AAV vectors are generally used for the administration of gene therapies to patients, given their ability to transduce various types of tissues and cells. The TESSA technology, developed by WuXi ATU, addresses industry demand for largescale production of AAV, by producing higher quality particles more efficiently.

The TESSA technology has also been scaled up to 200L, which resulted in a ten-fold increase in yield, as well as a higher full AAV capsids percentage. This, in turn, helped reduce the overall costs of AAV manufacturing, in comparison with other plasmid-based AAV production systems.

WuXi Advanced Therapies’ Chief Executive Office, Dr. David Chang, commented on the agreement, expressing his appreciation for Janssen’s decision to select the TESSA technology. He also reinforced the company’s commitment to enhancing the TESSA platform, in order to increase the production and cost-effectiveness of AAV products for patients in need.

WuXi AppTec is a global firm with operations across Europe, North America, and Asia, with an extensive portfolio of manufacturing and R&D services that facilitate the discovery and delivery of advanced treatments to patients. In 2021, the company received an AA ESG rating from MSCI, with its open-access health platform enabling over 5,850 collaborators across 30 nations to improve patient health.

The company also announced plans to establish a new manufacturing and research site in Singapore, earlier this year, to expand and enhance the capabilities of its integrated enabling platform to a global consumer base.

Source Credit: https://www.wuxiapptec.com/news/wuxi-news/5170

About Author

Pranali Mehta     aeresearch.net

Pranali Mehta

A chemical engineer by qualification, Pranali Mehta has dutifully walked down the slated path and worked in the chemicals industry for a year. Her passion for writing however, pushed her into experimenting with the same as a career. With over three years of experience...

Read More